Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: Effect of bevacizumab/paclitaxel combination therapy

Wenlian Zhu, Yoshinori Kato, Dmitri Artemov

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to assess changes in the tumor microvasculature induced by combination antiangiogenic therapy in MCF-7 breast tumor mouse models, using a noninvasive DCE-MRI method that minimizes the effect of water exchange. Materials and methods: 3D quantitative DCE-MRI images were acquired with a heavily T 1-weighted saturation recovery gradient echo sequence with a recovery delay of 20 ms. Tumor vascular volume (VV) and vascular permeability-surface area product (PS) were obtained through a linear regression of the albumin-Gd-DTPA-enhanced dynamic image intensity on MCF-7 breast tumor mouse models treated with combination bevacizumab/paclitaxel therapy. Results: Measured tumor VV values were significantly higher than the values that have been reported previously using quantitative T 1 mapping, and are in good agreement with micro-CT (computed tomography) results reported earlier from other tumor models. A trend of decreasing tumor PS was detected in the group of MCF-7 tumor bearing mice treated with the bevacizumab/paclitaxel combination regimen. Conclusion: VV and PS maps obtained by a heavily T 1-weighted acquisition protocol revealed the large peripheral blood vessels as well as the permeable areas within the tumor. A 12-day/three-dose combination treatment of bevacizumab and paclitaxel resulted in delayed tumor growth and a trend of decreasing tumor vascular permeability surface area product.

Original languageEnglish (US)
Pages (from-to)161-170
Number of pages10
JournalMagma (New York, N.Y.)
Volume27
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Paclitaxel
Blood Vessels
Water
Neoplasms
Capillary Permeability
Tumor Burden
Therapeutics
Breast Neoplasms
Microvessels
Bevacizumab
Linear Models
Tomography
Growth

Keywords

  • Combination antiangiogenic therapy
  • DCE-MRI
  • Tumor vascular volume and vascular permeability
  • Water exchange

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters : Effect of bevacizumab/paclitaxel combination therapy. / Zhu, Wenlian; Kato, Yoshinori; Artemov, Dmitri.

In: Magma (New York, N.Y.), Vol. 27, No. 2, 2014, p. 161-170.

Research output: Contribution to journalArticle

@article{5c4033995e6640568131a06217e83166,
title = "Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: Effect of bevacizumab/paclitaxel combination therapy",
abstract = "Objective: The purpose of this study was to assess changes in the tumor microvasculature induced by combination antiangiogenic therapy in MCF-7 breast tumor mouse models, using a noninvasive DCE-MRI method that minimizes the effect of water exchange. Materials and methods: 3D quantitative DCE-MRI images were acquired with a heavily T 1-weighted saturation recovery gradient echo sequence with a recovery delay of 20 ms. Tumor vascular volume (VV) and vascular permeability-surface area product (PS) were obtained through a linear regression of the albumin-Gd-DTPA-enhanced dynamic image intensity on MCF-7 breast tumor mouse models treated with combination bevacizumab/paclitaxel therapy. Results: Measured tumor VV values were significantly higher than the values that have been reported previously using quantitative T 1 mapping, and are in good agreement with micro-CT (computed tomography) results reported earlier from other tumor models. A trend of decreasing tumor PS was detected in the group of MCF-7 tumor bearing mice treated with the bevacizumab/paclitaxel combination regimen. Conclusion: VV and PS maps obtained by a heavily T 1-weighted acquisition protocol revealed the large peripheral blood vessels as well as the permeable areas within the tumor. A 12-day/three-dose combination treatment of bevacizumab and paclitaxel resulted in delayed tumor growth and a trend of decreasing tumor vascular permeability surface area product.",
keywords = "Combination antiangiogenic therapy, DCE-MRI, Tumor vascular volume and vascular permeability, Water exchange",
author = "Wenlian Zhu and Yoshinori Kato and Dmitri Artemov",
year = "2014",
doi = "10.1007/s10334-013-0389-0",
language = "English (US)",
volume = "27",
pages = "161--170",
journal = "Magnetic Resonance Materials in Physics, Biology, and Medicine",
issn = "0968-5243",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters

T2 - Effect of bevacizumab/paclitaxel combination therapy

AU - Zhu, Wenlian

AU - Kato, Yoshinori

AU - Artemov, Dmitri

PY - 2014

Y1 - 2014

N2 - Objective: The purpose of this study was to assess changes in the tumor microvasculature induced by combination antiangiogenic therapy in MCF-7 breast tumor mouse models, using a noninvasive DCE-MRI method that minimizes the effect of water exchange. Materials and methods: 3D quantitative DCE-MRI images were acquired with a heavily T 1-weighted saturation recovery gradient echo sequence with a recovery delay of 20 ms. Tumor vascular volume (VV) and vascular permeability-surface area product (PS) were obtained through a linear regression of the albumin-Gd-DTPA-enhanced dynamic image intensity on MCF-7 breast tumor mouse models treated with combination bevacizumab/paclitaxel therapy. Results: Measured tumor VV values were significantly higher than the values that have been reported previously using quantitative T 1 mapping, and are in good agreement with micro-CT (computed tomography) results reported earlier from other tumor models. A trend of decreasing tumor PS was detected in the group of MCF-7 tumor bearing mice treated with the bevacizumab/paclitaxel combination regimen. Conclusion: VV and PS maps obtained by a heavily T 1-weighted acquisition protocol revealed the large peripheral blood vessels as well as the permeable areas within the tumor. A 12-day/three-dose combination treatment of bevacizumab and paclitaxel resulted in delayed tumor growth and a trend of decreasing tumor vascular permeability surface area product.

AB - Objective: The purpose of this study was to assess changes in the tumor microvasculature induced by combination antiangiogenic therapy in MCF-7 breast tumor mouse models, using a noninvasive DCE-MRI method that minimizes the effect of water exchange. Materials and methods: 3D quantitative DCE-MRI images were acquired with a heavily T 1-weighted saturation recovery gradient echo sequence with a recovery delay of 20 ms. Tumor vascular volume (VV) and vascular permeability-surface area product (PS) were obtained through a linear regression of the albumin-Gd-DTPA-enhanced dynamic image intensity on MCF-7 breast tumor mouse models treated with combination bevacizumab/paclitaxel therapy. Results: Measured tumor VV values were significantly higher than the values that have been reported previously using quantitative T 1 mapping, and are in good agreement with micro-CT (computed tomography) results reported earlier from other tumor models. A trend of decreasing tumor PS was detected in the group of MCF-7 tumor bearing mice treated with the bevacizumab/paclitaxel combination regimen. Conclusion: VV and PS maps obtained by a heavily T 1-weighted acquisition protocol revealed the large peripheral blood vessels as well as the permeable areas within the tumor. A 12-day/three-dose combination treatment of bevacizumab and paclitaxel resulted in delayed tumor growth and a trend of decreasing tumor vascular permeability surface area product.

KW - Combination antiangiogenic therapy

KW - DCE-MRI

KW - Tumor vascular volume and vascular permeability

KW - Water exchange

UR - http://www.scopus.com/inward/record.url?scp=84898059203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898059203&partnerID=8YFLogxK

U2 - 10.1007/s10334-013-0389-0

DO - 10.1007/s10334-013-0389-0

M3 - Article

C2 - 23807596

AN - SCOPUS:84898059203

VL - 27

SP - 161

EP - 170

JO - Magnetic Resonance Materials in Physics, Biology, and Medicine

JF - Magnetic Resonance Materials in Physics, Biology, and Medicine

SN - 0968-5243

IS - 2

ER -